Introduction {#s1}
============

*Mycobacterium leprae*, an obligate intracellular pathogen and the etiologic agent of leprosy, cannot be grown in axenic medium. This characteristic, in conjunction with its extremely slow generation time of 12--14 days, hinders experimentation addressing even the most fundamental questions regarding its genetics, metabolism, sensitivity to anti-microbials, and pathogenicity. Live animal models are required for bacterial cultivation. Limited growth occurs in the footpads (FPs) of conventional mice [@pntd.0002404-Shepard1], [@pntd.0002404-Levy1], whereas more prolific growth is attained in immunosuppressed rodents [@pntd.0002404-Rees1]--[@pntd.0002404-Chehl1] and armadillos [@pntd.0002404-Kirchheimer1]. In these models bacterial multiplication is measured in terms of months to years.

Microscopic counting of acid fast bacilli (AFB) is used to enumerate *M. leprae* [@pntd.0002404-Levy1], [@pntd.0002404-Shepard2], [@pntd.0002404-Truman1]. Although this method is considered the gold standard, it is time consuming, labor intensive and restricted with regard to specificity. It conveys the total number of bacteria present and does not distinguish between live and dead bacilli. More recently, a molecular technique for the enumeration of *M. leprae* based on real time PCR amplification of the repetitive element, RLEP, was described [@pntd.0002404-Truman2]. RLEP PCR had correlative results with microscopic counting and allowed for rapid and specific quantification of *M. leprae* from both mouse and armadillo tissues. Like microscopic counting, it does not provide absolute data on the viability of *M. leprae*. AFB counts and RLEP PCR yield viability information only indirectly, as bacterial numbers increase over time in a growing population.

For many years, the only way to truly assess the viability of a particular population of *M. leprae* was to inoculate serial dilutions of freshly harvested bacilli into the FPs of passage mice [@pntd.0002404-Colston2], [@pntd.0002404-Welch1]. Requiring hundreds of mice and at least a year of subculture to complete, this method, while effective, is highly impractical due to the length of time to obtain results, as well as the cost and numbers of experimental animals required. In an effort to simplify and expedite viability determination for *M. leprae*, a number of assays have been developed which investigate surrogate markers of viability, such as cell wall integrity or metabolism. These include measurement of morphologic index [@pntd.0002404-Shepard3], [@pntd.0002404-Kaur1], PGL-1 synthesis [@pntd.0002404-Ramasesh1], [@pntd.0002404-Franzblau1], generation of intracellular ATP [@pntd.0002404-Franzblau1]--[@pntd.0002404-Agrawal1], palmitic acid oxidation in the BACTEC system [@pntd.0002404-Truman1], [@pntd.0002404-Franzblau2] and by radiorespirometry (RR) [@pntd.0002404-Truman1], [@pntd.0002404-Ramasesh2], [@pntd.0002404-Agrawal1], [@pntd.0002404-Franzblau3], [@pntd.0002404-Agrawal2], and various viability stains [@pntd.0002404-Katoch1], [@pntd.0002404-Kvach1]--[@pntd.0002404-Lahiri1]. Currently, the most commonly used techniques are RR and the BacLight viability stain [@pntd.0002404-Lahiri1].

Improved methods for viability determination that are more sensitive and user friendly would be helpful for clinical and research purposes. A number of molecular assays have been proposed for determining *M. leprae* viability in environmental or clinical samples based on 16S ribosomal RNA [@pntd.0002404-Lavania1]--[@pntd.0002404-Martinez1] or messenger RNA (mRNA) ([@pntd.0002404-Patel1], [@pntd.0002404-Chae1]. Recently, a quantitative reverse transcription (qRT)-PCR based molecular assay was developed for *M. leprae* which used a gene transcript for *sodA* mRNA [@pntd.0002404-Martinez1]. This assay was 100% specific for *M. leprae* and applicable as a viability indicator for bacilli recovered from short term macrophage cultures. Furthermore, the molecular data from the in vitro experiments showed a strong correlation with RR and BacLight viability staining.

The current studies built upon these principles with three objectives in mind. First, we sought to develop a sensitive and simple molecular assay which could accurately determine viability of *M. leprae* in infected tissue. Second, we examined the feasibility of eliminating the bacterial isolation steps and determining viability using nucleic acids isolated from ethanol-fixed FP tissues. Lastly, we evaluated the capacity of the molecular assays to monitor drug efficacy by comparing two leprosy drugs in a high bacterial burden, athymic mouse FP model. Results showed that when compared to the conventional methods of RR and BacLight viability staining, the *hsp18* and *esxA* qRT-PCR assays were sensitive and reliable biological indicators of *M. leprae* viability in tissues, and that concomitant host gene expression could be monitored from the same RNA preparations.

Materials and Methods {#s2}
=====================

Ethics statement {#s2a}
----------------

These studies were performed under a scientific protocol reviewed and approved by the National Hansen\'s Disease Programs Institutional Animal Care and Use Committee (Assurance \#A3032-01), and were conducted in accordance with all state and federal laws in adherence with PHS policy and as outlined in *The Guide to Care and Use of Laboratory Animals, Eighth Edition*.

*M. leprae* and infection of mice {#s2b}
---------------------------------

*M. leprae*, strain Thai-53, is maintained in athymic *nu/nu* mice through serial passage. Freshly harvested bacilli are stored at 4°C and used within 24 hours of harvest [@pntd.0002404-Truman1]. In this study, BALB/c and athymic *nu/nu* mice (Harlin Sprague-Dawley, Inc., Indianapolis, IN) were infected by inoculating each hind FP with 3×10^7^ *M. leprae* in 0.03 ml PBS (Irvine Scientific, Santa Ana, CA) [@pntd.0002404-Hagge1], [@pntd.0002404-Adams1]. FPs were harvested on Day 1 post infection and at 4, 8, 12 and 17 weeks.

Drug treatment {#s2c}
--------------

At 18 weeks post infection, groups of *M. leprae*-infected *nu/nu* mice were treated, by gavage, with rifampin (RMP, 10 mg/kg) or rifapentine (RPT, 10 mg/kg) emulsified in hydroxypropyl-β-cyclodextrin/L-α-phosphatidylcholine. All drugs were purchased from Sigma-Aldrich (St. Louis, MO). Each drug was administered as a single dose, five daily doses, or twenty daily doses (5 days per week for 4 weeks). Control mice were given vehicle only. FPs were harvested 1 month after completion of treatment for each regimen.

Mouse FP harvest {#s2d}
----------------

The feet were disinfected with 70% ethanol and Betadine, the skin removed, and the FP tissue excised. Viable *M. leprae* were collected immediately from the right FPs. The left FP tissues were stored in 70% ethanol at −20°C until processed for DNA and RNA purification.

*M. leprae* isolation {#s2e}
---------------------

To harvest the bacilli, the right FP tissues were minced and gently homogenized in hand-held Tenbroeck tissue glass grinders (Fisher Scientific, Pittsburgh, PA) in 2.5 ml RPMI (Life Technologies, Grand Island, NY) containing 50 µg/ml ampicillin (Sigma-Aldrich) and trypsin. After incubation at 37°C for 15 minutes and slow speed centrifugation (100× g) for 1 minute to remove most of the tissue debris, the supernatants were pelleted (10,000× g for 30 minutes), resuspended, and sonicated in RPMI+10% FBS (Hyclone Laboratories, Logan, UT)+ampicillin. These bacterial suspensions were subjected to microscopic counting, BacLight viability staining, and RR.

Microscopic counting of AFB {#s2f}
---------------------------

Three smears were prepared from each FP sample and counts of bacilli in twenty microscopic fields per smear were calculated to determine the number of AFB present in that particular FP [@pntd.0002404-Shepard2]. Data are reported as mean +/− S.D. of 4--10 mice per group.

Radiorespirometry (RR) {#s2g}
----------------------

RR was performed as described previously [@pntd.0002404-Truman1]. Briefly, *M. leprae* from individual FPs were suspended in 1.0 ml of BACTEC 7H12B medium (Becton Dickinson, Franklin Lakes, NJ) in a 6 ml glass shorty vial (Wheaton Industries Inc., Millville, NJ) with a loosened cap. The vial was placed into a liquid scintillation vial with a 2″×4″ strip of Whatman \#42 filter paper (Fisher Scientific) that had been soaked in Kodak concentrate I (Eastman Kodak Co., Rochester, NY) and dried. ^14^CO~2~ evolution was measured daily for seven days. Results were calculated as cpm ^14^CO~2~ per 10^6^ bacilli and reported as mean +/− S.D. of 4--10 mice per group.

Viability staining {#s2h}
------------------

*M. leprae* from individual FPs were washed twice in sterile saline and stained using a BacLight Viability Staining Kit (Life Technologies) as previously described [@pntd.0002404-Lahiri1]. Briefly, the bacterial suspension was incubated for 15 minutes at room temperature in 6 µM Syto9 and 30 µM propidium iodine. The bacteria were washed with sterile saline and the pellet resuspended in 5% glycerol in saline. Five µl of the suspension was spread onto a slide, and viability was determined by counting the red and green bacilli, indicating dead and live bacteria, respectively, under a Nikon fluorescence microscope. The excitation/emission maxima are 480 nm/500 nm for Syto9 and 490 nm/635 nm for propidium iodide. Results are calculated as percent viability and reported as mean +/− S.D. of 4--10 mice per group.

Purification of nucleic acids {#s2i}
-----------------------------

RNA and DNA were purified from the left FPs using a previously described protocol [@pntd.0002404-Martinez1]. Individual fixed FPs were removed from the ethanol, rehydrated, minced, suspended in 1.0 ml TRIzol reagent, and homogenized twice in FastRNA blue tubes using the FastPrep FP 24 instrument (MP Biomedicals, Solon, OH). Tubes were chilled on ice for 5 minutes, after which 200 µl of chloroform-isoamyl alcohol was added. After vortexing for 10 seconds and centrifugation at 700× g at 4°C for 5 minutes, the supernatants were transferred to new tubes, spun again at 14,000× g for 10 minutes, and the RNA collected from 300 µl of the aqueous phase. After incubation at −70°C overnight, the precipitated RNA was resuspended in 30 µl DEPC treated water, and contaminating DNA was removed using a Turbo DNA-free kit (Life Technologies). The purified RNA (150 µl) was stored at −70°C. DNA was purified by adding 100 µl of 10 mM Tris-EDTA and 150 µl of chloroform-isoamyl alcohol to the remaining aqueous phase and interphase material, homogenizing in the FastPrep 24 FP instrument twice, and centrifuging at 14,000× g for 10 minutes. The aqueous phase (200 µl) was precipitated with 5 M ammonium acetate and two volumes of cold ethanol, incubated at −70°C overnight, washed in 70% ethanol, dissolved in 30 µl 1× TE, and stored at −70°C.

Reverse transcription {#s2j}
---------------------

RNA from 3×10^3^ *M. leprae*, as determined from the number of RLEP genome equivalents from each specimen, was reverse transcribed. Titration experiments had shown that RNA from this number of *nu/nu* mouse-derived viable bacilli would consistently give a strong signal in the RT-PCR reactions. The RNA was converted to cDNA using an Advantage RT-for-PCR kit (Clontech, Mountain View, CA) consisting of reverse transcriptase, Advantage cDNA polymerase mix, and random hexamer primers at 42°C for 1 hour, 94°C for 5 minutes, and 4°C for 5 minutes. For mouse gene expression, 1 µg RNA was reverse transcribed to cDNA using the same conditions. Control for DNA contamination consisted of equivalent amounts of RNA, polymerase mix, and primers without the reverse transcriptase.

Taqman {#s2k}
------

Molecular enumeration of *M. leprae* was determined using the purified DNA fraction from each specimen via Taqman technology using primers and a probe for a common region of the RLEP family of dispersed repeats in *M. leprae* as previously described [@pntd.0002404-Truman2]. Molecular viability of *M. leprae* was determined using the cDNA generated from the RNA fraction for each specimen and qRT-PCR. Primers and probes for each target sequence were designed using Primer Express 2.0 software (Life Technologies): *hsp*18 primers: forward -- cgatcgggaaatgcttgc, reverse -- cgagaaccagctgacgattg, probe - 6Fam-acaccgcgtggccgctcg; esxA primers: forward -- ccgagggaataaaccatgca, reverse -- cgtttcagccgagtgattga, probe - 6Fam-tgcttgcaccaggtcgccca. Five µl cDNA were added to the reaction mixture and real time PCR was performed using cycling conditions of 40 cycles of 60°C annealing, extension for 60 seconds, and 95°C denaturation for 15 seconds. PCR and data analyses for all assays were performed on a 7300 RealTime PCR System (Life Technologies). Results of the Taqman assays were applied to a standard curve generated by preparing 4-fold serial dilutions of a known number of *M. leprae*. Results were reported as mRNA equivalents for each gene transcript analyzed.

Mouse gene expression was evaluated utilizing cDNA and commercially available specific primer sets and probes for TNF, IFNγ, and CCL-2, and Universal Master Mix (Life Technologies). Data was analyzed by the ΔΔC~T~ method and expressed as a log-fold increase in expression over uninfected FPs. GAPDH was used to normalize for template variation. Results are reported as mean +/− S.D. of 4--10 mice per group.

Statistical analyses {#s2l}
--------------------

Data were analyzed using unpaired *t* tests or the non-parametric Mann-Whitney test and compared by group and within a group over time using SigmaPlot 12.0 software (Systat Software, Inc, Chicago, IL). Data was considered significant at P\<0.05.

Results {#s3}
=======

Evaluation of *M. leprae* viability in mouse FPs using conventional assays {#s3a}
--------------------------------------------------------------------------

Microscopic counting of AFB is shown in [Figure 1A](#pntd-0002404-g001){ref-type="fig"}. On Day 1 post infection, 4.78×10^6^±1.30×10^6^ and 5.03×10^6^±2.23×10^6^ AFB were recovered from the BALB/c and *nu/nu* FPs, respectively. This recovery of approximately 16% of the inoculum is typical considering the architecture of the mouse FP and is consistent with previous reports [@pntd.0002404-Truman2], [@pntd.0002404-Levy2]. In the *nu/nu* FPs, the number of *M. leprae* steadily increased over the infection period reaching 4.25×10^8^±3.46×10^8^ by 17 weeks post infection (p\<0.001). In contrast, the number of AFB in the BALB/c FPs remained steady at 4 weeks and then declined at 8 (p\<0.001), 12 (p = 0.006), and 17 (p = 0.035) weeks.

![Enumeration and quantification of *M. leprae* in mouse FPs using conventional assays.\
BALB/c (gray bars) and athymic *nu/nu* (black bars) mice were infected in the FPs with 3×10^7^ *M. leprae*. Bacilli were harvested on day 1 and at 4, 8, 12, and 17 weeks post infection and enumerated by direct counting (A). Viability of *M. leprae* was determined by BacLight viability staining (B) and RR (C). Dotted line represents the lower detection limit of the assay. Bars represent mean and standard deviation for each group. The value at each time point was compared to its respective value at 1 day. \* = probability of statistical significance (p)\<0.05, \*\* = probability of statistical significance (p)\<0.01, and \*\*\* = probability of statistical significance (p)\<0.001.](pntd.0002404.g001){#pntd-0002404-g001}

The conventional viability assays, BacLight staining and RR, were performed on *M. leprae* isolated from the BALB/c and *nu/nu* mouse FPs throughout the infection period to determine its viability. Using the BacLight staining method ([Figure 1B](#pntd-0002404-g001){ref-type="fig"}), *M. leprae* from BALB/c and *nu/nu* FPs were 78.71±10.53 and 82.34±7.87 percent viable, respectively, on Day 1. Percent viability increased to 90.51±4.90 in the *nu/nu* FPs by 12 weeks (p = 0.029) post infection. In BALB/c mice, *M. leprae* viability decreased to 60.72±7.16 percent by 4 weeks (p\<0.001) and to 29.79±8.90 percent by 8 weeks (p\<0.001) post infection. Percent viability held at this level for the remainder of the infection period.

Using the RR assay ([Figure 1C](#pntd-0002404-g001){ref-type="fig"}), *M. leprae* viability reported as ^14^CO~2~ generated per 10^6^ bacilli showed a slight increase by 4weeks (p = 0.049) in the *nu/nu* mice. In contrast, *M. leprae* from BALB/c FPs exhibited a 1.5 log decline in metabolic activity by 4weeks post infection (p\<0.001).

Molecular evaluation of *M. leprae* viability in mouse FPs {#s3b}
----------------------------------------------------------

RLEP enumeration, performed on DNA purified from the left FP tissues, demonstrated that 6.27×10^6^±5.88×10^6^ *M. leprae* were recovered from BALB/c FPs and 4.07×10^6^±3.78×10^6^ were recovered from *nu/nu* FPs on Day 1 ([Figure 2A](#pntd-0002404-g002){ref-type="fig"}). An initial lag phase was evident in the *nu/nu* FPs yet growth reached 9.70×10^7^±1.35×10^8^ (p = 0.015) by 17 weeks post infection. In the BALB/c FPs, there was a significant decrease in the number of *M. leprae* at 4 (p = 0.022), 8 (p = 0.003), 12 (p\<0.001) and 17 (p = 0.002) weeks.

![Enumeration and quantification of *M. leprae* in mouse FPs by molecular assays.\
BALB/c (gray bars) and athymic *nu/nu* (black bars) mice were infected in with 3×10^7^ *M. leprae*. FP tissues were fixed in 70% ethanol on day 1 and at 4, 8, 12, and 17 weeks post infection. DNA and RNA were purified using a FastPrep protocol. *M. leprae* were enumerated by RLEP PCR on the DNA fraction (A). cDNA was prepared from an RNA equivalent of 3×10^3^ *M. leprae* for determination of viability by *hsp18* (B) and *esxA* (C) qRT-PCR. Bars represent mean and standard deviation for each group. The value at each time point was compared to its respective value at 1 day. \* = probability of statistical significance (p)\<0.05, \*\* = probability of statistical significance (p)\<0.01, and \*\*\* = probability of statistical significance (p)\<0.001.](pntd.0002404.g002){#pntd-0002404-g002}

*hsp18* and *esxA* qRT-PCR assays yielded strong signals when evaluated for use as indicators of *M. leprae* viability in our models. In both assays, expression of the transcripts was maintained in the *nu/nu* FPs on the order of ∼10^5^ *hsp18* ([Figure 2B](#pntd-0002404-g002){ref-type="fig"}) or *esxA* ([Figure 2C](#pntd-0002404-g002){ref-type="fig"}) equivalents per 3×10^3^ *M. leprae* over the course of infection. In contrast, these assays demonstrated a sharp decline in viability in the BALB/c FPs by 8 weeks to 1.95×10^3^±8.76×10^2^ for *hsp18* (p\<0.001) and 4.30×10^3^±1.69×10^3^ for *esxA* (p\<0.001), and remained on the order of 10^3^ equivalents for the remainder of the infection period.

RMP and RPT Treatment of *M. leprae*-infected mice {#s3c}
--------------------------------------------------

The conventional and molecular assays were compared in a multibacillary FP model for their capacity to monitor drug efficacy. Athymic *nu/nu* mice were infected with 3×10^7^ *M. leprae*. At 18 weeks post infection, rifampin or rifapentine (each at 10 mg/kg) were administered to groups of mice for 1 treatment (1×), 5 daily treatments (5×) or 20 doses at 5 days per week for 4 weeks (20×). FPs were harvested 1 month post treatment for each regimen.

Results of the conventional viability assays are shown in [Figure 3](#pntd-0002404-g003){ref-type="fig"}. One treatment with rifampin or rifapentine did not decrease *M. leprae* viability when measured by BacLight staining ([Figure 3A](#pntd-0002404-g003){ref-type="fig"}) or RR ([Figure 3B](#pntd-0002404-g003){ref-type="fig"}). Rifapentine reduced *M. leprae* viability to 56.83±4.11 percent (p\<0.001) after 5 daily treatments and to 27.78±6.05 percent (p\<0.001) with 20 doses as measured by BacLight staining ([Figure 3A](#pntd-0002404-g003){ref-type="fig"}). Twenty doses of rifampin decreased viability to 37.71±6.79 percent (p = 0.057). Rifampin was more effective when assessed using the RR assay ([Figure 3B](#pntd-0002404-g003){ref-type="fig"}) and decreased *M. leprae* metabolic activity by approximately 1 log (p\<0.001) after 5 treatments. Rifapentine treatment reduced metabolism \>2 log (p = 0.016). Both rifampin and rifapentine were active at 20× (p = 0.016).

![Enumeration and quantification using conventional assays of *M. leprae* from RMP and RPT treated mice.\
Athymic *nu/nu* (black bars) mice were infected in the FPs with 3×10^7^ *M. leprae*. At 18 weeks post infection, groups of mice were treated with 1 dose (1×), 5 daily doses (5×), or 20 daily doses (20×) of RMP (striped bars) or RPT (crosshatched bars), each at 10 mg/kg. Control mice received vehicle alone (gray bars). One month after the last dose of each regimen, bacilli were harvested and viability of *M. leprae* was determined by BacLight viability staining (A) and RR (B). Dotted line represents the lower detection limit of the assay. Bars represent mean and standard deviation for each group. \* = probability of statistical significance (p)\<0.05, and \*\*\* = probability of statistical significance (p)\<0.001.](pntd.0002404.g003){#pntd-0002404-g003}

In agreement with the conventional viability assays, neither rifampin nor rifapentine at a single dose decreased *M. leprae* viability when assessed by *hsp18* ([Figure 4A](#pntd-0002404-g004){ref-type="fig"}) or *esxA* ([Figure 4B](#pntd-0002404-g004){ref-type="fig"}) qRT-PCR. Control FPs expressed ∼10^5^ *hsp18* or *esxA* equivalents per 3×10^3^ *M. leprae*. Five doses of rifapentine reduced this to 1.88×10^3^±1.37×10^3^ *hsp18* (p = 0.001) and 3.04×10^3^±1.33×10^3^ *esxA* (p = 0.001) equivalents, while 5× rifampin showed no significant decrease in expression in either assay. However, these molecular assays demonstrated that both rifampin and rifapentine were highly effective at 20 doses when measured by *hsp18* expression (p = 0.016 and p = 0.019, respectively) or *esxA* expression (p\<0.001 and p = 0.009, respectively).

![Enumeration and quantification via molecular assays of *M. leprae* from RMP and RPT treated mice.\
Athymic *nu/nu* (black bars) mice were infected in the FPs with 3×10^7^ *M. leprae*. At 18 weeks post infection, groups of mice were treated with 1 dose (1×), 5 daily doses (5×), or 20 daily doses (20×) of RMP (striped bars) or RPT (crosshatched bars), each at 10 mg/kg. Control mice received vehicle alone (gray bars). One month after the last dose of each regimen, FP tissues were fixed in 70% ethanol. DNA and RNA were purified using a FastPrep protocol. *M. leprae* were enumerated by RLEP PCR on the DNA fraction, and cDNA was prepared from an RNA equivalent of 3×10^3^ *M. leprae* for determination of viability by *hsp18* (A) and *esxA* (B) qRT-PCR. Bars represent mean and standard deviation for each group. \* = probability of statistical significance (p)\<0.05, \*\* = probability of statistical significance (p)\<0.01, and \*\*\* = probability of statistical significance (p)\<0.001. 5× RPT vs. 20× RPT: (p) = 0.396 for *hsp18*; (p) = 0.569 for *esxA*.](pntd.0002404.g004){#pntd-0002404-g004}

Host gene expression in *M. leprae*-infected FPs {#s3d}
------------------------------------------------

The RNA preparations were also examined for cytokine and chemokine expression. As shown in [Table 1](#pntd-0002404-t001){ref-type="table"}, high levels of TNF were expressed by Day 1in the FPs of both strains of mice. TNF expression increased in BALB/c FPs by 8 weeks (p = 0.031) but decreased in *nu/nu* FPs (p = 0.028). Little or no IFNγ was expressed by either strain on Day 1, but expression increased by \>2 log in BALB/c (p\<0.001). IFNγ expression also increased in *nu/nu* FPs (p = 0.005) but not to the extent of BALB/c. Similar levels of CCL-2 were expressed by both strains at both time points.

10.1371/journal.pntd.0002404.t001

###### Host gene expression in *M. leprae*-infected mouse FPs.

![](pntd.0002404.t001){#pntd-0002404-t001-1}

  Strain/Time[a](#nt101){ref-type="table-fn"}    TNF[b](#nt102){ref-type="table-fn"}     p     IFNγ[b](#nt102){ref-type="table-fn"}      p      CCL-2[b](#nt102){ref-type="table-fn"}   p
  --------------------------------------------- ------------------------------------- ------- -------------------------------------- --------- --------------------------------------- ----
  BALB/c                                                                                                                                                                               
  T0                                                          1.65±0.40                                     0.44±0.36                                         1.10±0.34                
  T+8 weeks                                                   2.04±0.30                0.031                2.21±0.31                 \<0.001                 1.40±0.88                 NS
  *nu/nu*                                                                                                                                                                              
  T0                                                          1.53±0.46                                     0.00±0.27                                         0.93±0.42                
  T+8 weeks                                                   1.16±0.26                0.028                0.50±0.41                  0.005                  2.12±1.08                 NS

Mice were infected with 3×10^7^ *M. leprae*. FP tissues were harvested and fixed in 70% ethanol on Day 1 and at 8 weeks post infection. RNA was purified using a FastPrep protocol, and cDNA was prepared from 1 µg RNA and subjected to PCR for TNF, IFNγ and CCL-2.

Data was normalized to GAPDH and expressed as a log-fold increase over uninfected FPs.

Discussion {#s4}
==========

The lack of an *in vitro* cultivation system for *M. leprae* has made determination of its viability extremely difficult in experimental models of the disease and in human lesions because current techniques require large numbers of purified, viable bacteria. This restricts investigation into the pathogenicity of *M. leprae* as well as the experimental testing of novel drugs for the treatment of leprosy. Therefore, the purpose of this study was to develop a simple and sensitive molecular assay for determining *M. leprae* viability directly from infected tissues. Two *M. leprae*-specific qRT-PCR assays based on the expression levels of *esxA* and *hsp18* were developed and tested in the mouse FP model using both immunocompetent and immunocompromised mice. These qRT-PCR assays could detect high viability in the athymic *nu/nu* FP as well as killing of *M. leprae* by the host immune system in the BALB/c mouse, or by antimicrobial treatment of *nu/nu* mice having highly multibacillary FPs. The RNA preparations were also successfully used for detection of host cytokine expression.

The hypothesis tested in this study was that viability is related to the expression of specific genes; therefore, monitoring a specific *M. leprae* gene transcript(s) by qRT-PCR should provide a simple and sensitive assay for determining its viability. Molecular methods have been developed to ascertain the viability of several infectious organisms [@pntd.0002404-Keer1]. Early studies used levels of ribosomal RNA as a marker of viability [@pntd.0002404-McKillip1]--[@pntd.0002404-Aarthi1]. However, its long half-life and inconsistent retention made it somewhat less accurate, especially for short term experimentation. Because of its relatively short half-life, mRNA has been used successfully as a viability indicator for a number of pathogens [@pntd.0002404-Sheridan1]--[@pntd.0002404-Alum1] including *M. tuberculosis* [@pntd.0002404-Hellyer1]--[@pntd.0002404-Li1]. The choice of transcript was an important consideration in all of these studies, not only for sensitivity but also for its expression under a variety of circumstances. In addition, different viability assays have varying abilities to differentiate cell death, which is often highly dependent on how the organism is killed and how cell death is defined [@pntd.0002404-Sheridan1], [@pntd.0002404-Villarino2].

Initially we tested the expression profiles of several *M. leprae* genes as potential indicators of viability in our system. These included: *sodA*, encoding superoxide dismutase A and which was used successfully in the *M. leprae*-infected macrophage cultures [@pntd.0002404-Martinez1]; *gap*, encoding glyceraldehyde-3-phosphate dehydrogenase; ML2138C, encoding a probable transmembrane protein; *hsp18*, encoding the 18 kD heat shock protein; and *esxA*, encoding the ESAT-6 protein. These transcripts were chosen based on their high expression levels in DNA microarray experiments at 6 months post infection in the athymic *nu/nu* FP model [@pntd.0002404-Williams1]. However, *sodA*, *gap*, and ML2138C genes were not transcribed in sufficient quantities at the early time points in the FP models and therefore did not possess the requisite sensitivity (data not shown). In contrast, the *hsp18* and *esxA*-based assays were highly expressed in both immunocompetent and immunosuppressed mice. Moreover, they were both able to accurately determine loss of viability when using two different methods of bacterial killing, i.e. immunologically mediated and anti-microbial drugs, which strengthens the validity and usefulness of these assays.

In the present study, athymic *nu/nu* and BALB/c mouse FPs were inoculated with a relatively high dose of *M. leprae*. We chose this dose for infection because, as an immunizing dose in BALB/c immunocompetent mice, it would be recognized and killed in the first 1--2 months of infection; yet, in the immunocompromised athymic *nu/nu* mice the inoculum would continue to grow. When inoculated with fewer *M. leprae*, (e.g., 10^3^ to 10^4^), the maximum growth attained in an immunocompetent mouse FP is approximately 10^6^ bacilli [@pntd.0002404-Shepard1]. This growth plateau, which is seen at approximately 6 months post infection, is due to death of the bacilli by the immune response. Once bacterial numbers peak, viability decreases with a half-time of loss of 25 days [@pntd.0002404-Welch1]. Using the *hsp18* and *esxA* qRT-PCR assays, a strong signal could be obtained with RNA from 3×10^3^ *M. leprae*.

Over the years a variety of techniques have been developed in an attempt to circumvent the inability to culture this organism. Each assay measures different aspects of *M. leprae* viability and has provided insights into its unique properties. For our conventional viability determinations, we used RR [@pntd.0002404-Truman1], [@pntd.0002404-Ramasesh2], [@pntd.0002404-Agrawal1], [@pntd.0002404-Franzblau3], [@pntd.0002404-Agrawal2] and BacLight viability staining [@pntd.0002404-Lahiri1]. RR measures the oxidation of ^14^C-palmitic acid to ^14^CO~2~; thus, viability is defined in terms of the metabolic activity of the bacterial population. Viability staining uses fluorescent dyes that bind nucleic acids, with one dye that can penetrate cell membranes and one that cannot. A differential staining pattern is exhibited by live bacteria with intact cell membranes versus dead bacteria with damaged membranes. Thus, viability in this assay is assessed in terms of membrane integrity of individual bacteria. While these assays work very well for in vitro viability determinations, and for ex vivo use, they also have their limitations. Both require immediate, labor intensive purification of *M. leprae* and processing of samples as the bacilli rapidly lose viability once removed from the host. The bacterial population must be relatively clean and free of most host tissue debris to obtain clear results, especially for the BacLight assay. For RR, a minimum of 10^6^ organisms are required for accurate readings. Furthermore, matters regarding the use of radioisotopes, including worker safety and waste disposal, must be considered. Although valuable in the laboratory, these conditions make these assays impractical for evaluating *M. leprae* viability in biopsy specimens in clinical or field settings where the reagents and equipment required for bacterial isolation and viability assessment are not readily available.

Therefore, in conjunction with the development of the molecular assays, we evaluated the feasibility of eliminating the bacterial isolation steps and assessing viability on nucleic acids purified directly from ethanol-fixed FP tissue. Our success with this protocol certainly indicates potential for use with biopsy specimens in the clinic or field. Although we have not evaluated formalin-fixed paraffin-embedded tissue (FFPE) for RT-PCR, Su, et al. [@pntd.0002404-Su1] have shown that ethanol fixation for samples slated for RT-PCR is far superior to FFPE and that these tissues can be stored for weeks. Our unpublished results show that RNA can be preserved for months in 70% ethanol at room temperature. Thus, tissues can be easily fixed and stored in 70% ethanol for transport back to the laboratory for processing [@pntd.0002404-Fiallo1], [@pntd.0002404-Williams2].

A potential application for these molecular viability assays is in the monitoring of treatment. Lesions of multibacillary patients often contain numerous bacilli even years after completion of multidrug therapy, inciting concern over the possibility of inadequate treatment, lack of compliance, or drug resistance. Our studies using well defined models, i.e. immunocompetent and athymic *nu/nu* mice infected with a well characterized inoculum [@pntd.0002404-Truman1] of known viability and duration of infection, have allowed characterization of the optimum parameters for use of the *hsp18* and *esxA* transcripts as viability indicators for *M. leprae* in tissues. Further studies, of course, must be done to determine whether these parameters will suffice for assessing viability of *M. leprae* in patient samples.

RMP is a very effective anti-leprosy drug and an integral part of the WHO multidrug regimen [@pntd.0002404-Scollard1]. Early investigations with RMP found it to be more rapidly bactericidal than dapsone [@pntd.0002404-Rees2], [@pntd.0002404-Shepard4], with reports that even a single treatment of patients rendered *M. leprae* non-infectious for mice [@pntd.0002404-Levy3]. Similarly, treatment of *M. leprae*-infected immunocompetent mice with a single dose of RMP had a significant bactericidal effect [@pntd.0002404-Shepard4], [@pntd.0002404-Ji1]--[@pntd.0002404-Ji3]. Subsequently, several investigators examined various therapeutic regimens, with and without RMP, using *M. leprae* infection of athymic *nu/nu* mice. The *nu/nu* model removes the likely contribution of the immune system to aid the drug therapy in its bactericidal effects and treatment of a high bacterial burden, "lepromatous" infection can be tested. The efficacy of rifampin in this model has been variable [@pntd.0002404-Hastings1]--[@pntd.0002404-Banerjee2]. Early studies showed that single [@pntd.0002404-Banerjee1] or intermittent [@pntd.0002404-Hastings1] dosing with RMP was not effective and that 99.99% killing was not achieved with each dose.

In a large, well-controlled trial designed to determine the effectiveness of single dose rifampicin to prevent leprosy in close contacts in a high endemic area, Moet, et al. [@pntd.0002404-Moet1] found a 57% reduction in the overall incidence of leprosy in the treatment group at 2 years. This efficacy was maintained but not improved at 4 and 6 years of follow-up [@pntd.0002404-Moet1], [@pntd.0002404-Feenstra1]. However, when they evaluated subgroups of contacts, chemoprophylaxis with single dose rifampicin was less effective in contacts of patients with multibacillary disease and in contacts that were seropositive for PGL-1. They postulated that the bacillary load in these contacts at the time of treatment may have already been too high to be eliminated.

In our present study, the purpose of the RMP and RPT treatments was to validate the molecular viability assays, and we used a high bacterial burden, lepromatous model. Neither a single dose nor 5 daily doses of RMP were effective when measured by either BacLight staining or the molecular assays, although a decrease in metabolic activity was detected by RR after 5 doses. Treatment with 20 daily doses, however, showed strong inhibition in all assays. RPT, in contrast was effective at 5 daily doses, likely due to its longer retention and more potent anti-mycobacterial activity [@pntd.0002404-Ji3], [@pntd.0002404-Ji5]--[@pntd.0002404-Almeida1]. Altogether, these collective findings underscore the adjunctive role played by immunity in successful chemotherapy and emphasize the issues which must be considered when treating the susceptible host.

An added bonus to monitoring gene expression in situ is that host gene expression can be determined using the same RNA preparations. If using the conventional assays in our experimental studies, separate groups of mice must be employed for host gene expression and *M. leprae* enumeration and viability determinations. With the molecular assays, both host and bacterial expression can be determined using the same RNA samples, thereby greatly reducing the number of animals required for an experiment. Likewise, successful application of these techniques in the clinical setting could enable the monitoring of *M. leprae* viability and correlation with the immune response. A particular need would be during the treatment of reactional episodes, an aspect of leprosy which is still poorly understood.

In conclusion, these results show that the *hsp18* and *esxA* qRT-PCR assays are reliable indicators for determining *M. leprae* viability in tissue specimens. Their sensitivity and simplicity make them useful for initial in vivo drug screening. Moreover, their ease of use makes them attractive for potential application in clinical and field settings, and both *M. leprae* viability as well as host responses during treatment can be monitored.
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